Journal article icon

Journal article

Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218).

Abstract:

The invention described in this review (WO2013030218) relates to compounds based on the quinazolin-4-one scaffold, their process of preparation and applications to inhibit the ubiquitin-specific protease 7 (USP7), a deubiquitinating enzyme (DUB), which is considered a potentially important new drug target for treating cancer and immunological disorders. Data are presented indicating that these small-molecule compounds are useful as selective and reversible inhibitors of USP7 in vitro and also...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Publisher:
Informa Healthcare
Journal:
Expert opinion on therapeutic patents More from this journal
Volume:
24
Issue:
5
Pages:
597-602
Publication date:
2014-05-01
DOI:
EISSN:
1744-7674
ISSN:
1354-3776
Language:
English
Keywords:
Pubs id:
pubs:446663
UUID:
uuid:08c8d826-f1ea-43d1-b8cf-b0cd8ef641ed
Local pid:
pubs:446663
Source identifiers:
446663
Deposit date:
2014-01-30

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP